| GSK dodges bullet as second generic Advair bid fails | | | LONDON (Reuters) - GlaxoSmithKline looks unlikely to face competition from a substitutable copy of its blockbuster lung drug Advair in the United States this year, after a second generic application was turned down by U.S. regulators. |
| |
| Pfizer strikes deal with Sangamo, broadening hemophilia pipeline | | | NEW YORK (Reuters) - U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A, under which Pfizer will pay $70 million upfront. |
| |
| Vermont legislature approves marijuana legalization bill | | | BOSTON (Reuters) - Vermont lawmakers on Wednesday approved a measure to legalize recreational use of marijuana, which if not vetoed by the governor would make the state the ninth to legalize the drug and the first to do so by legislation rather than ballot initiative. |
| |
| U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer | | | (Reuters) - Merck & Co said on Wednesday U.S. health regulators approved its Keytruda in combination with chemotherapy for previously untreated advanced lung cancer, solidifying the drugmaker's lead position in the field of medicines that help the immune system fight cancer. |
| |
| | |
